Evidence map›Paper›PMID 34249225›Full record

ReviewWorld journal of stem cells2021

Immunotherapy in the treatment of lymphoma.

Lazar S Popovic, Gorana Matovina-Brko, Maja Popovic, Milica Popovic, Ana Cvetanovic, Ivan Nikolic, Biljana Kukic, Dragana Petrovic

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lazar S PopovicDepartment for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia. lazar.popovic@mf.uns.ac.rs.
Gorana Matovina-BrkoDepartment for Medical Oncology, Oncology Institute of Vojvodina, Novi Sad 21000, Serbia.
Maja PopovicDepartment for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia.
Milica PopovicDepartment for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia.
Ana CvetanovicDepartment for Medical Oncology, Clinical Center of Nis, University of Nis, Nis 18000, Serbia.
Ivan NikolicDepartment for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia.
Biljana KukicDepartment for Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad 21000, Serbia.
Dragana PetrovicDepartment for Medical Oncology, Oncology Institute of Vojvodina, Novi Sad 21000, Serbia.
University of Novi Sad · RSOncology Institute of Vojvodina · RSUniversity of Nis · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated with salvage regimens, and if eligible for aggressive therapy, treatment is continued with high-dose chemotherapy and autologous stem cell transplantation. Current therapy options can cure substantial numbers of patients, however for some it is still an uncurable disease. Numerous new drugs and cell therapies are being investigated for the treatment of relapsed or refractory lymphomas. Different types of immunotherapy options have shown promising results, and some have already become the standard of care. Here, we review immunotherapy options for the treatment of lymphoma and discuss the results, positions, practical aspects, and future directions of different drugs and cellular therapies for the treatment of this disease.

Indexed as

AntibodiesChimeric antigenDiffuseHodgkin diseaseImmunoconjugatesImmunotherapyLarge B-cellLymphomaMonoclonalReceptors

Identifiers

PMID34249225
PMCPMC8246244
OpenAlexW3174682887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.